About Us
History
SanaCurrents was founded after developing a set of objective data points related to clinical trials and regulatory decisions in drug and device development. When important medical treatments achieve key milestones, or catalysts, patients benefit and the values of biotech and device companies increase.
The data points provide the foundation for SanaCurrents’ proprietary analytics-based model, which identifies the therapies and companies SanaCurrents believes most likely to increase in value prior to a catalyst announcement. Examples of catalyst announcements include compelling results of a clinical study or the publication of data in an influential scientific journal.
SanaCurrents’ first forecast related to Kite Pharma’s CAR-T immunotherapy, KTE-C19. In 2016, SanaCurrents predicted Kite would announce positive results of its pivotal trial of KTE-C19. The stock jumped 24% on the day of the announcement to $55.17. Approximately one year later, Gilead purchased Kite for $180 per share.
Sana is the imperative form of the verb sano in Latin, which means “to heal or to cure now.” SanaCurrents tracks the course, or current, of the important medicines of tomorrow.
The partners, based in California, invest according to the model.
Bill Langbein
Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work.
One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Unfortunately, small medical companies are inherently volatile. The recent emergence of precision medicine, however, mitigates this volatility and increases the potential for the alpha returns SanaCurrents seeks.
Philip Greyling
Shortly after SanaCurrents was started, Philip Greyling joined while he was a graduate student. Philip has completed an undergraduate degree in molecular biology and a professional science master’s (PSM) program. The PSM provided advanced training in innovative scientific techniques as well as skills in management and analytics. At SanaCurrents, Philip specializes in scientific analysis and stock selection.